"I am honored to join the Company at this pivotal time as we advance our human clinical trials and create a strategic regulatory program for the Continuous Blood Glucose Monitor (CBGM),” said Mr.
23, Mike Snyder, lead author and former postdoctoral scholar at Stanford Medicine, along with his team of researchers, detailed their research using AI to help sub-classify Type II diabetes through a ...
GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable ...